首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1917832

總體基因體學市場－2026-2031年預測

Metagenomics Market - Forecast from 2026 to 2031

出版日期: 2026年01月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計總體基因體學市場將從 2025 年的 29.16 億美元成長到 2031 年的 48.6 億美元，複合年成長率為 8.89%。

元基因組總體基因體學涵蓋了分析直接從環境和臨床樣本中提取的集體遺傳物質（DNA/RNA）所需的各種技術、服務和生物資訊工具。這種方法無需分離和培養單一微生物，即可提供整個微生物群落組成、功能和動態的客觀見解。該市場的發展主要得益於次世代定序（NGS）平台、專用樣品製備盒、用於數據分析的先進計算軟體以及相關的實驗室服務。這代表著微生物學領域的模式轉移，使得在實驗室研究絕大多數無法培養的微生物成為可能，釋放了以往難以觸及的生物多樣性和功能潛力。

市場擴張的根本驅動力在於高價值研究和商業領域的變革性應用。總體基因體學在藥物發現和開發中日益重要的角色是關鍵的成長要素。篩檢環境和宿主相關的微生物組，研究人員能夠識別具有治療潛力的新型生物合成基因叢集、酵素和生物活性化合物，在抗菌素抗藥性日益嚴重的時代，為研發新型抗生素、抗癌藥物和其他藥物提供強力的途徑。同時，總體基因體學正在革新臨床診斷。諸如鳥槍法元基因組組定序等技術能夠實現無需預設假設的病原體檢測、集體爆發監測以及複雜微生物組-疾病關聯的闡明，其應用範圍已從單一病原體檢測擴展到全面的感染疾病和菌群失調分析。

另一個重要的促進因素是核心平台技術的持續進步。新一代定序（NGS）技術的創新，例如更長的讀長、更高的通量和更低的鹼基成本，使得大規模元基因組調查變得更加容易。同樣重要的是生物資訊學的進步，包括更強大的序列組裝、分類和功能註釋演算法，這些對於將原始數據轉化為生物學見解至關重要。尤其重要的是長讀長定序技術的整合，它能夠從複雜的混合物中重建完整的微生物基因組，並提高分析精度。

從地理來看，亞太地區正崛起為重要的高成長市場，這大規模得益於政府和私部門對生命科學研究，特別是藥物研發和精準醫療舉措的大量投資。各國為提升國內生物技術能力而製定的策略，正在催生對先進基因組學工具和服務的高度需求，使亞太地區成為市場擴張和戰略投資的關鍵區域。

然而，儘管宏基因組學潛力巨大，但其市場推廣仍面臨許多障礙，主要與成本和複雜性相關。總體基因體學的總成本仍然很高，包括用於高通量定序的大量計算資源、專門的樣本製備以及數據存儲和分析。這種成本結構對於資金雄厚的研究中心以外的小規模學術實驗室、醫院和企業來說可能構成障礙。此外，該領域需要分子生物學、微生物學、生物資訊學和統計學等多種專業知識的綜合運用。缺乏能夠進行穩健的研究設計、處理複雜資料集以及在生物學背景下解讀結果的熟練人員是阻礙因素。

競爭格局的特點是：大規模成熟的生命科學工具和診斷公司提供整合平台（定序儀、耗材和軟體），而專業的生物資訊公司和服務供應商提供端到端的分析流程。競爭的焦點在於分類和功能分析的準確性和深度、分析軟體的易用性和計算效率，以及提供能夠降低終端用戶技術門檻的承包解決方案的能力。成功的關鍵不僅在於處理大量資料集，還在於建立擴充性、可重複且可解釋的工作流程，從而提供可操作的生物學見解。

總之，總體基因體學市場正引領我們理解和利用微生物世界能力的根本性擴展。其成長的結構性基礎在於治療方法發現和先進診斷等關鍵應用，並由持續的技術進步所驅動。對業內人士而言，策略重點應放在普及應用上，透過更自動化、基於雲端的解決方案降低成本並簡化生物資訊學的複雜性。未來的創新將聚焦於即時、可攜式定序應用、多體學資料（宏轉錄組學、代謝體學）的整合，以及開發標準化資料庫和分析框架，以提高研究間的可比較性。在這個市場取得成功不僅需要提供強大的工具，還需要建立必要的整合生態系統，將複雜的遺傳數據轉化為檢驗的科學發現以及切實可行的臨床和產業成果。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The metagenomics market encompasses the technologies, services, and bioinformatics tools required to analyze the collective genetic material (DNA/RNA) recovered directly from environmental or clinical samples, bypassing the need for isolating and culturing individual organisms. This approach provides an unbiased view of the composition, function, and dynamics of entire microbial communities. The market is propelled by next-generation sequencing (NGS) platforms, specialized library preparation kits, sophisticated computational software for data analysis, and associated laboratory services. It represents a paradigm shift in microbiology, enabling the study of the vast majority of microbes that are unculturable in the lab, thereby unlocking previously inaccessible biological diversity and functional potential.

Market expansion is fundamentally driven by its transformative applications across high-value research and commercial sectors. A primary growth catalyst is the burgeoning role of metagenomics in drug discovery and development. By screening environmental and host-associated microbiomes, researchers can identify novel biosynthetic gene clusters, enzymes, and bioactive compounds with therapeutic potential, offering a powerful route to new antibiotics, anticancer agents, and other pharmaceuticals in an era of rising antimicrobial resistance. Concurrently, metagenomics is revolutionizing clinical diagnostics. Techniques like shotgun metagenomic sequencing enable hypothesis-free pathogen detection, outbreak surveillance, and the characterization of complex microbiome-disease associations, moving beyond single-pathogen tests to comprehensive infectious disease and dysbiosis profiling.

A parallel and powerful driver is the continuous advancement of core enabling technologies. Innovations in NGS, such as increased read lengths, higher throughput, and reduced costs per base, are making large-scale metagenomic surveys more accessible. Equally critical are developments in bioinformatics, including more powerful algorithms for sequence assembly, taxonomic classification, and functional annotation, which are essential for transforming raw sequence data into biological insights. The integration of long-read sequencing technologies is particularly significant, improving the reconstruction of complete microbial genomes from complex mixtures and enhancing the accuracy of analyses.

Geographically, the Asia-Pacific region is emerging as a significant and high-growth market, propelled by substantial governmental and private investments in life sciences research, particularly in drug discovery and precision medicine initiatives. National strategies to build domestic biotechnology capacity are creating a concentrated demand for advanced genomic tools and services, positioning APAC as a key region for market expansion and strategic investment.

Despite its immense potential, the market faces substantial adoption barriers, primarily related to cost and complexity. The total expense of a metagenomics study remains significant, encompassing high-throughput sequencing runs, specialized sample preparation, and substantial computational resources for data storage and analysis. This cost profile can be prohibitive for smaller academic labs, hospitals, or industries outside of well-funded centers. Furthermore, the field requires a rare combination of expertise in molecular biology, microbiology, bioinformatics, and statistics. The scarcity of skilled personnel capable of designing robust studies, processing complex datasets, and interpreting results within a biological context is a major constraint on broader implementation.

The competitive landscape is characterized by large, established life science tools and diagnostics companies that provide integrated platforms (sequencers, consumables, software), alongside specialized bioinformatics firms and service providers offering end-to-end analytical pipelines. Competition centers on the accuracy and depth of taxonomic and functional profiling, the user-friendliness and computational efficiency of analysis software, and the ability to deliver turnkey solutions that lower the technical barrier for end-users. Success hinges on creating scalable, reproducible, and interpretable workflows that deliver actionable biological insights, not just vast datasets.

In conclusion, the metagenomics market is at the forefront of a fundamental expansion in our ability to understand and harness the microbial world. Its growth is structurally supported by critical applications in therapeutic discovery and advanced diagnostics, powered by relentless technological progress. For industry experts, strategic focus must center on democratizing access by driving down costs and simplifying bioinformatic complexity through more automated, cloud-based solutions. Future innovation will likely focus on real-time, portable sequencing applications, the integration of multi-omics data (metatranscriptomics, metabolomics), and the development of standardized databases and analytical frameworks to improve comparability across studies. Success in this market requires providing not just powerful tools, but the integrated ecosystem necessary to translate complex genetic data into validated scientific discoveries and tangible clinical or industrial outcomes.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Metagenomics Market Segmentation

By Type
Targeted Sequencing
Shot-Gun Sequencing
By Application
Disease Diagnostics
Vaccine Development
Drug Discovery
Others
By End-User
Pharmaceutical & Biotech Companies
Academic & Research Institutes
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. METAGENOMICS MARKET BY TYPE

5.1. Introduction
5.2. Targeted Sequencing
5.3. Shot-Gun Sequencing

6. METAGENOMICS MARKET BY APPLICATION

6.1. Introduction
6.2. Disease Diagnostics
6.3. Vaccine Development
6.4. Drug Discovery
6.5. Others

7. METAGENOMICS MARKET BY END-USER

7.1. Introduction
7.2. Pharmaceutical & Biotech Companies
7.3. Academic & Research Institutes
7.4. Others

8. METAGENOMICS MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others